These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 35908759)

  • 1. Medicinal cannabis for the treatment of anxiety disorders.
    Berger M; Amminger GP; McGregor IS
    Aust J Gen Pract; 2022 Aug; 51(8):586-592. PubMed ID: 35908759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.
    Trevitt BT; Bailey S; Mills L; Arkell TR; Suraev A; McGregor IS; Lintzeris N
    PLoS One; 2024; 19(2):e0297092. PubMed ID: 38354169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A primer on medicinal cannabis safety and potential adverse effects.
    Arnold JC
    Aust J Gen Pract; 2021 Jun; 50(6):345-350. PubMed ID: 34059837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.
    Sarris J; Sinclair J; Karamacoska D; Davidson M; Firth J
    BMC Psychiatry; 2020 Jan; 20(1):24. PubMed ID: 31948424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Use of Δ9-THC and Cannabidiol: Evaluation of a New Extraction Procedure for the Preparation of Cannabis-based Olive Oil.
    Morini L; Porro G; Liso M; Groppi A
    Curr Pharm Biotechnol; 2017; 18(10):828-833. PubMed ID: 29189144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis.
    Hutten NRPW; Arkell TR; Vinckenbosch F; Schepers J; Kevin RC; Theunissen EL; Kuypers KPC; McGregor IS; Ramaekers JG
    Psychopharmacology (Berl); 2022 Nov; 239(11):3731-3741. PubMed ID: 36227352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental
    Bidwell LC; Martin-Willett R; Skrzynski C; Lisano J; Ortiz Torres M; Giordano G; Hutchison KE; Bryan AD
    Cannabis Cannabinoid Res; 2024 Aug; 9(4):1015-1027. PubMed ID: 38252547
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals.
    Legare CA; Raup-Konsavage WM; Vrana KE
    Pharmacology; 2022; 107(3-4):131-149. PubMed ID: 35093949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping cannabis potency in medical and recreational programs in the United States.
    Cash MC; Cunnane K; Fan C; Romero-Sandoval EA
    PLoS One; 2020; 15(3):e0230167. PubMed ID: 32214334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of Medical Cannabis.
    Amin MR; Ali DW
    Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol in medical marijuana: Research vistas and potential opportunities.
    Rong C; Lee Y; Carmona NE; Cha DS; Ragguett RM; Rosenblat JD; Mansur RB; Ho RC; McIntyre RS
    Pharmacol Res; 2017 Jul; 121():213-218. PubMed ID: 28501518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties.
    Sharpe L; Sinclair J; Kramer A; de Manincor M; Sarris J
    J Transl Med; 2020 Oct; 18(1):374. PubMed ID: 33008420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of prior foot shock stress and Δ
    Rock EM; Limebeer CL; Petrie GN; Williams LA; Mechoulam R; Parker LA
    Psychopharmacology (Berl); 2017 Jul; 234(14):2207-2217. PubMed ID: 28424834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort.
    Baron EP; Lucas P; Eades J; Hogue O
    J Headache Pain; 2018 May; 19(1):37. PubMed ID: 29797104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use.
    Pichini S; Mannocchi G; Berretta P; Zaami S; Pirani F; Pacifici R; Busardò FP
    Ther Drug Monit; 2020 Feb; 42(1):151-156. PubMed ID: 31389860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.
    Szaflarski JP; Bebin EM
    Epilepsy Behav; 2014 Dec; 41():277-82. PubMed ID: 25282526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabis update: Anxiety disorders and post-traumatic stress disorder.
    Haycraft AL
    J Am Assoc Nurse Pract; 2023 May; 35(5):276-280. PubMed ID: 37000126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
    Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
    Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.